刘燕青,周欣蓓,蔡尚郎

• 1:青岛大学附属医院心内科

摘要(Abstract)：

<正>慢性心力衰竭是各种心血管疾病的严重或终末阶段,是由于各种原因使初始心肌损伤引起的心室充盈和射血能力受损,导致心室泵血功能降低。血流动力学改变,神经、体液及内分泌因子所致的心肌重塑是其发生发展的基本机制[1]。慢性心力衰竭发病率高,5年存活率与恶性肿瘤相仿,严重威胁着人们的身体健康及生活质量[2]。随着老龄化及城市化进程加快,慢性心力衰竭已成为重大公共健康问题[2-3]。目前,药物治疗给患者带来了诸多益处,但尚不能完全遏制心力衰竭的进展,而近年来器械治疗的发展一定程度上改善了慢性心力衰竭患者预后。当下,两种基于心房分流的新设备已逐渐应用于临床治疗慢性心力衰竭且取得了初步成功。本文就慢性

关键词(KeyWords)： 慢性心力衰竭;房间隔分流装置;V-Wave装置

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘燕青,周欣蓓,蔡尚郎

参考文献(References)：

• [1]黎励文,李明敏.慢性心力衰竭的治疗进展.中华老年心脑血管病杂志, 2016, 18(7):673-675.
• [2] Heidenreich PA, Aibert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States:a policy statement form the American Heart Association. Circ Heart Fail, 2013, 6(3):606-619.
• [3] Kang SH, Oh IY, Kang DY, et al. Cardiac resynchronization therapy and QRS duration:systematic review, meta-analysis, and meta-regression. J Korean Med Sci, 2015, 30(1):24-33.
• [4] Graham AJ, Providenica R, Honarbakhsh S, et al. Systematic review and meta-analysis of left ventricular endocardial pacing in advanced heart failure:clinically efficacious bur at what coat?Pacing Clin Elecrtophysiol, 2018, 41(4):353-361.
• [5] Forleo GB, Santini L, Giammaria M, et al. Multipoint pacing via a quadripolar left-ventricular lead:preliminary results from the Italian registry on multipoint left-ventricular pacing in cardiac resynchronization therapy(IRON-MPP). Europace, 2017, 19(7):1170-1177.
• [6] Tomassoni G, Baker J 2nd, Corbisiero R, et al. Rationale and design of a randomized trial to assess the safety and efficacy of Multi Point Pacing(MPP)in cardiac resynchronization therapy:the MPP trial. Ann Noninvasive Electrocardiol, 2017, 22(6):1-8.
• [7] Siciliano M, Migliore F, Badano L, et al. Cardiac resynchronization therapy by multipoint pacing improves response of left ventricular mechanics and fluid dynamics:a three-dimensional and particle image velocimetry echo study. Europace, 2017, 19(11):1-8.
• [8]邹彤,佟佳宾,施海峰,等.左心室四极导线在心脏再同步化治疗中的临床应用.中国介入心脏病学杂志,2017, 25(2):72-76.
• [9] Bettin M, Reinke F, Rath B, et al. Recent advances in the entirely subcutaneous ICD system. F1000Prime Rep, 2015, 7:46.
• [10] Al-Ghamdi B, Shafquat A, Alruwaili N, et al. Subcutaneous implantable cardioverter defibrillators implantation without defibrillation threshold testing:a single center experience. Cardiol Res, 2017, 8(6):319-326.
• [11] Barsheshet A, Kutyifa V, Vamvouris T, et al. Study of the wearable cardioverter defibrillator in advanced heart-failure patients(SWIFT).J Cardiovasc Electrophysiol, 2017, 28(7):778-784.
• [12] Lee LC, Ge L, Zhang Z, et al. Patient-specific finite element modeling of the Cardiokinetix Parachute(?)device:effects on left ventricular wall stress and function. Med Biol Eng Comput, 2014,52(6):557-566.
• [13] Yang YJ, Huo Y, Xu YW, et al. Percutaneous ventricular restoration therapy using the parachute device in Chinese patients with ischemic heart failure:three-month primary end-point results of PARACHUTE China study. Chin Med J, 2016, 129(17):2058-2062.
• [14] Abi-Samra F, Gutterman D. Cardiac contractility modulation:a novel approach for the treatment of heart failure. Heart Fail Rev,2016, 21(6):645-660.
• [15] Müller D, Remppis A, Schauerte P, et al. Clinical effects of longterm cardiac contractility modulation(CCM)in subjects with heart failure caused by left ventricular systolic dysfunction. Clin Res Cardiol, 2017, 106(11):893-904.
• [16] Cuthbert JJ, Pellicori P, Clark AL. Interatrial shunt devices for heart failure with normal ejection fraction:a technology update.Med Devices(Auckl), 2017, 10:123-132.
• [17] Hasenfu?G, Hayward C, Burkho?D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction(REDUCE LAP-HF):a multicentre, open-label, singlearm, phase 1 trial. Lancet, 2016, 387(10025):1298-1304.
• [18] Tsch?pe C, Birner C, B?hm M, et al. Heart failure with preserved ejection fraction:current management and future strategies. Clin Res Cardiol, 2018, 107(1):1-19.
• [19] Bozkurt B. What is new in heart failure management in 2017?Update on ACC/AHA heart failure guidelines. Curr Cardiol Rep,2018, 20(6):39.
• [20] Lutembacher R. De la stenose mitrale avec communication interauriculaire. Arch Mal Coeur, 1916, 9:237-260.
• [21] Tadic M, Cuspidi C, Frydas A, et al. The role of arterial hypertension in development heart failurewith preserved ejection fraction:just a risk factor or something more? Heart Fail Rev,2018, 23(5):631-639.
• [22] Kaye DM, Hasenfu?G, Neuzil P, et al. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail, 2016, 9(12):e003662.
• [23] Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction(REDUCE LAP-HF I[reduce elevated left atrial pressure in patients with heart failure]). Circulation, 2018, 137(4):364-375.
• [24] Amat-Santos IJ, Bergeron S, Bernier M, et al. Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure:first-in-man experience with the V-Wave device. EuroIntervention, 2015, 10(9):1127-1131.
• [25] Del Trigo M, Bergeron S, Bernier M, et al. Unidirectional left-toright interatrial shunting for treatment of patients with heart failure with reduced ejection fraction:a safety and proof-of-principle cohort study. Lancet, 2016, 387(10025):1290-1297.
• [26] Bauer A, Khalil M, Lüdemann M, et al. Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction:effective palliation of left atrial hypertension and pulmonary congestion. Clin Res Cardiol, 2018, 107(9):845-857.